

Screening of Reverse Transcriptase Inhibitor from *Moringa oleifera* Bioactive Compound through In Silico Study Against HIV-1

Received 14 Desember 2022,
Accepted 21 Desember 2022,

DOI: 10.1039/sainstek/vol1-
iss02/9

Ahmad Affan Ali Murtadlo^{1*}, Sri Wahyuningsih², Dora Dayu Rahma Turista³, Arbi Wiguna⁴, Arini Wijayanti⁵, Yuanita Rachmawati⁶, Alyaa Farrah Dibha⁷, Thobib Hasan⁸, Renadya Maulani Wijaya⁹, Muhammad Aldino Hafidzhah⁹, Santika Lusya Utami², Priscilla Listiyani¹, Agus Mohammad Hikam¹⁰, Nelson Chandra⁹, Muhammad Badrut Tamam¹¹, Md. Emdad Ullah¹²

¹Computational Virology Research Unit, Molecular Biology and Genetics Division, Generasi Biologi Indonesia Foundation, Gresik Indonesia.

²Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, Indonesia.

³Educational Biology Department, Faculty of Teacher Training and Education, Mulawarman University, Samarinda, Indonesia.

⁴Zoology Division, Generasi Biologi Indonesia Foundation, Gresik, Indonesia.

⁵Department of Ecology and Evolutionary Biology, University of California Santa Cruz, Santa Cruz, United States.

⁶Department of Biology, Faculty of Science and Technology, UIN Sunan Ampel Surabaya, Surabaya, Indonesia.

⁷Chemistry Department, Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, Indonesia.

⁸Department of Biology, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia.

⁹Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life-Sciences, East Jakarta, Indonesia.

¹⁰Faculty of Mathematics and Natural Sciences, Universitas Islam Malang, Malang, Indonesia.

¹¹Department of Biology, Faculty of Sciences and Technology, Universitas Muhammadiyah Lamongan, Lamongan, Indonesia.

¹²Department of Chemistry, Mississippi State University, Mississippi State, United States.

*Corresponding author: ahmadaffan171@gmail.com

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) from the retrovirus family can trigger opportunistic diseases of the immune system or AIDS. In these conditions the immune system fails due to infection with bacteria, protozoa, fungi, and other viruses. HIV-1 has several enzymes consisting of reverse transcriptase (RT), integrase (INT), & protease (PR), all of which play an important role in the replication process. Reverse transcriptase plays a role in the formation of HIV-1 cDNA in several stages consisting of lysyl tRNA having a binding site, RT then adds a nucleotide to synthesize cDNA

† Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/sainstek/vol1-iss02/9

to the non-coding or U5 and R (repeat) region of the viral RNA. RT activity has a crucial role in viral replication and is very likely to be a target in drug design. This study aims to reveal the molecular mechanism of compounds from *Moringa oleifera* to be antiviral for HIV-1 through a bioinformatics approach. Kaempferitrin and β -sitosterol from *Moringa oleifera* are predicted to be HIV-1 antiviral agents. Both compounds can produce more negative binding affinity and weak bond interactions. This indicates the stability of the binding interaction that triggers the inhibitory activity.

Keywords: Bioactive, HIV-1, In Silico, *Moringa oleifera*, Reverse Transcriptase

INTRODUCTION

Human immunodeficiency virus type 1 (HIV-1) from the retrovirus family can trigger opportunistic diseases of the immune system or AIDS. In these conditions the immune system fails due to infection with bacteria, protozoa, fungi, and other viruses. The identified types of HIV consist of HIV-1 & HIV-2, HIV-1 has a higher infectious nature than HIV-2 because of the genetic drift mechanism^{1,2}. Several HIV-1 strains such as A, B, C, D, E, F, G, H, & J were obtained from Africa, Asia, Europe, Australia, and America. HIV-1 has structural genes consisting of env, gag, and pol then essential elements & regulators such as rev, tat, nef, vpr, vpu, and vif that play a role in helping the virus to evade the immune system's response and pathogenesis in host cells^{2,4}. Endemic cases of HIV-1 are often found and HIV-2 is very rare, therefore the development of antiretroviral drugs is currently focused on treating HIV-1 infection⁵. Research on HIV-1 vaccines is still in the research phase and some patients are only taking antiretrovirals to survive.

HIV-1 has several enzymes consisting of reverse transcriptase (RT), integrase (INT), & protease (PR), all of which play an important role in the replication process^{6,7}. Reverse transcriptase plays a role in the formation of HIV-1 cDNA in several stages consisting of lysyl tRNA having a binding site, RT then adds a nucleotide to synthesize cDNA to the non-coding or U5 and R (repeat) region of the viral RNA⁸. The RT region known as RNase H degrades U5 and R at the 5' end, then tRNA primers synthesize DNA strands^{9,10}. HIV-1 cDNA is carried by integrase to integrate with the host cell genome. RT activity has a crucial role in viral replication and is very likely to be a target in drug design.

Moringa oleifera is a medicinal plant for healthcare that has survived for a long time, WHO has recommended several natural ingredients and medicinal plants to be used as objects of health research^{11,12}. Several countries in Africa and Asia use *Moringa oleifera* for HIV antivirals

because there are several specific chemical compounds for drug candidates in these plants, the bioactive compounds from *Moringa oleifera* consist of vanillin, kaempferitrin, β -sitosterone, β -sitosterol, & kaempferol, but the molecular mechanism is not yet known¹³. This study aims to reveal the molecular mechanism of compounds from *Moringa oleifera* to be antiviral for HIV-1 through a bioinformatics approach.

METHOD

Ligand-protein preparation

This study used chemical compounds from *Moringa oleifera* consisting of vanillin, kaempferitrin, beta-sitosterone, beta-sitosterol, & kaempferol. Information on the 3D structure, Canonical SMILE, and CID of the target compound was obtained from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>)¹⁴. The HIV-1 reverse transcriptase (RT) protein was used as the target drug design in this study, 3D structure information was obtained from the RCSB PDB database (<https://www.rcsb.org/>)^{15,16}.

Structure minimization and water molecule cleaning

The energy minimization process on ligands with file structure data format (sdf) is carried out through OpenBabel v2.3.1 software, it aims to convert sdf files to pdb and increase the flexibility of query ligands¹⁷. Molecular cleaning is carried out through PyMol v2.5 software with the aim of removing water molecules, ions, and contaminants such as ligands for the effectiveness of the formation of binding energy in the docking simulation¹⁸.

Molecular docking study

The docking in this study aims to identify the binding energy or binding affinity which refers to the inhibitory ability of the ligand of *Moringa oleifera* when interacting with the HIV-1 RT domain¹⁹. This study uses a blind docking method for screening potential compounds from natural materials and simulations are carried out using PyRx v0.9.9 software²⁰. 3D visualization of docking

simulation results is displayed through PyMol v2.5 software with structural selection and coloring methods based on publication standards^{21,22}.

Chemical interaction

Molecular interactions in the compound complex from *Moringa oleifera* and HIV-1 RT with the strongest binding energy will be shown to determine the type of chemical bond and the position of the interaction^{23,24}. This research uses LigPlus v2.2.4 software to identify molecular interactions in the docked molecular complex²⁵.

RESULT AND DISCUSSION

Revealing of inhibitor molecular mechanism from *Moringa oleifera* compound

Moringa oleifera in people's lives around the world is used for traditional medicine such as anti-inflammatory, antiviral, preventing free radicals, and others^{26,27,28}. *Moringa oleifera* was identified to have chemical compounds consisting of Vanillin, Karpferittrin, β -sitosterone, β -sitosterol, and Kaempferol (Table 1). This study used a chemical compound from *Moringa oleifera* to identify candidate antiviral drugs against HIV-1 by inhibiting the activity of viral reverse transcriptase (RT) by molecular docking simulation with autogrid positions are Center (Å) X:25.084 Y: -22.972 Z: 17.618, Dimensions (Å) X: 106.090 Y: 112.360 Z: 103.725.

Table 1. *Moringa oleifera* chemical compound from PubChem

Compound	CID	Formula	SMILE Canonical
Vanillin	1183	C8H8O3	<chem>COC1=C(C=CC(=C1)C=O)O</chem>
Kaempferittrin	5486199	C27H30O14	<chem>CC1C(C(C(C(O1)OC2=CC(=C3C(=C2)OC(=C(C3=O)OC4C(C(C(C(O4)C)O)O)O)C5=CC=C(C=C5)O)O)O)O)O</chem>
β -sitosterone	9801811	C29H48O	<chem>CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(=O)C4)C)C(C)C</chem>
β -sitosterol	222284	C29H50O	<chem>CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C(C)C</chem>
Kaempferol	5280863	C15H10O6	<chem>C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O</chem>

Kaempferittrin and β -sitosterol has a binding affinity of -9.7 kcal/mol more negative than other compounds when it binds to E6 protein (Table 2), Kaempferittrin and β -sitosterol is predicted to inhibit the activity of RT in HIV-1 because it has more negative binding than other compounds. The molecular docking simulation aims to determine the activity of the ligand binding on the

protein domain by referring to the binding affinity value^{29,30,31,32}. The binding affinity value indicates the inhibitory ability of a ligand on the activity of the target protein. Visualization of docking results is displayed through cartoons structure and sticks with selected coloring (Figure 1).

Table 2. The comparison of compound binding affinity

Compound	Molecular Weight (g/mol)	RCSB Target ID	Minimize Energy (kcal/mol)	Binding Affinity (kcal/mol)
Vanillin	152.15	1REV	+79.78	-5.7
Kaempferittrin	578.5	1REV	+844.04	-9.7
β -sitosterone	412.7	1REV	+579.82	-8.0
β -sitosterol	414.7	1REV	+593.22	-9.7
Kaempferol	286.24	1REV	+357.41	-8.0




Figure 1. 3D Visualization from the docking results. (A) RT_Kaempferitrin (B) RT_β-sitosterol

Molecular interaction of *Moringa oleifera* compounds at HIV-1 RT

Weak binding interactions of ligand bonds can initiate specific biological activities such as protein inhibitory responses, these interactions are played by hydrogen bonds, hydrophobicity, van der Waals, and π ^{33,34,35}. Unfavorable interactions are unstable bonds formed in the molecular complex (ligand-protein) a stable ligand must have at least two unfavorable interactions^{36,37,38}. Hydrogen bond interactions have an important role in triggering a specific response to the target protein and are used as an indicator of the effectiveness of a drug's performance, the more types of hydrogen bonding

interactions on the target protein, the stronger the effect of the drug^{39,40,41,42,43}. Identification of molecular interactions and binding positions on the docked protein-ligand complex (Figure 2) showed that the bonding of kaempferitrin and β-sitosterol compounds in HIV-1 RT resulted in non-covalent bond interactions consisting of Van der Waals, π , hydrogen, and unfavorable interactions not detected (Table 3). All the weak binding interactions produced by kaempferitrin and β-sitosterol can contribute to the formation of stable ligand-protein complexes and initiate an inhibitory activity response in HIV-1 RT.

Table 3. Molecular interaction on HIV-1 RT pocket binding domain

Compounds	Molecular Interaction
Kaempferitrin	van der Waals: Ile142, Glu169, Gly141, Thr165, Pro140, Gln161, Trp88, Glu53 Hydrogen: Ser162, Pro52, Lys166, Ile50 Alkyl: Lys49, Arg143, Pro52, Lys166
β-sitosterol	van der Waals: Lys64, Thr409, Asp186, Gly231, Arg72, Asp110, Gln407, Ala408, Gln373, Lys374, Glu70, Met357, Tyr354 Alkyl: Lys65, Val108, Tyr232, Lys66




Figure 2. Positions and types of chemical bond interactions. (A) RT_Kaempferitrin (B) RT_β-sitosterol.

CONCLUSION

Kaempferitrin and β-sitosterol from *Moringa oleifera* are predicted to be HIV-1 antiviral agents. Both compounds can produce more negative binding affinity and weak bond interactions. This indicates the stability of the binding interaction that triggers the inhibitory activity. We recommend the RT-HIV-1 binding domain and two potential compounds from *Moringa oleifera* for further research as a target for HIV-1 drug design and the results of this study are yet to be verified through wet lab testing.

REFERENCES

- Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, Nussenzweig M, Pace C, Ho D, Bjorkman PJ, Baty D, Chames P, Pancera M, Kwong PD, Poignard P, Barin F, Braibant M. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. *J Virol.* 2014; 88(23): 13910-7. DOI: 10.1128/JVI.02083-14.
- Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M. Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. *PLoS Pathog.* 2013; 9(7): e1003477. DOI: 10.1371/journal.ppat.1003477.
- Ansori ANM, Fadholly A, Proboningrat A, Antonius Y, Hayaza S, Susilo RJ, Inayatillah B, Sibero MT, Naw SW, Posa GAV, Sucipto TH, Soegijanto S. Novel Antiviral Investigation of *Annona squamosa* Leaf Extract against the Dengue Virus Type-2: In vitro Study. *Phcog J.* 2021; 13(2): 456-462. DOI: 10.5530/pj.2021.13.58
- Ansori AN, Kharisma VD, Parikesit AA, Dian FA, Probojati RT, Rebezov M, Scherbakov P, Burkov P, Zhdanova G, Mikhalev A, Antonius Y, Pratama MRF, Sumantri NI, Sucipto TH, Zainul R. Bioactive Compounds from Mangosteen (*Garcinia mangostana* L.) as an Antiviral Agent via Dual Inhibitor Mechanism against SARS-CoV- 2: An In Silico Approach. *Phcog J.* 2022; 14(1): 85-90. DOI: 10.5530/pj.2022.14.12
- Wijaya RM, Hafidzhah MA, Kharisma VD, Ansori ANM, Parikesit AP. COVID-19 In Silico Drug with Zingiber officinale Natural Product Compound Library Targeting the Mpro Protein. *Makara J Sci.* 2021; 25(3): 5. DOI: 10.7454/mss.v25i3.1244
- Fahmi M, Kharisma VD, Ansori ANM, Ito M. Retrieval and Investigation of Data on SARS-CoV-2 and COVID-19 Using Bioinformatics Approach. *Adv Exp Med Biol.* 2021; 1318: 839-857. DOI: 10.1007/978-3-030-63761-3_47.

7. Winarni D, Husna FN, Syadzha MF, Susilo RJK, Hayaza S, Ansori ANM, Alamsjah MA, Amin MNG, Wulandari PAC, Pudjiastuti P, Awang K. Topical Administration Effect of *Sargassum duplicatum* and *Garcinia mangostana* Extracts Combination on Open Wound Healing Process in Diabetic Mice. *Scientifica*. 2022; 2022: 9700794. DOI: 10.1155/2022/9700794.
8. Khairullah AR, Solikhah TI, Ansori ANM, Hanisia RH, Puspitarani GA, Fadholly A, Ramandinianto SC. Medicinal importance of *Kaempferia galanga* L. (Zingiberaceae): A comprehensive review. *J Herbmec Pharmacol*. 2021; 10: 281-288. DOI: 10.34172/jhp.2021.32
9. Kharisma VD, Probojati RT, Murtadlo AAA, Ansori ANM, Antonius Y, Tamam MB. Revealing Potency of Bioactive Compounds as Inhibitor of Dengue Virus (DENV) NS2B/NS3 Protease from Sweet Potato (*Ipomoea batatas* L.) Leaves. *Indian J Forensic Med Toxicol*. 2020; 15(1): 1627–1632. DOI: 10.37506/ijfmt.v15i1.13644
10. Kharisma VD, Agatha A, Ansori ANM, Widyananda MH, Rizky WC, Dings TGA, Derkho M, Lykasova I, Antonius Y, Rosadi I, Zainul R. Herbal combination from *Moringa oleifera* Lam. and *Curcuma longa* L. as SARS-CoV-2 antiviral via dual inhibitor pathway: A viroinformatics approach. *J Pharm Pharmacogn Res*. 2022; 10(1): 138-146.
11. Xiong Y, Rajoka MSR, Mehwish HM, Zhang M, Liang N, Li C, He Z. Virucidal activity of *Moringa A* from *Moringa oleifera* seeds against Influenza A Viruses by regulating TFEb. *Int Immunopharmacol*. 2021; 95: 107561. DOI: 10.1016/j.intimp.2021.107561.
12. Feustel S, Ayón-Pérez F, Sandoval-Rodríguez A, Rodríguez-Echevarría R, Contreras-Salinas H, Armendáriz-Borunda J, Sánchez-Orozco LV. Protective Effects of *Moringa oleifera* on HBV Genotypes C and H Transiently Transfected Huh7 Cells. *J Immunol Res*. 2017; 2017:6063850. DOI: 10.1155/2017/6063850.
13. Vergara-Jimenez M, Almatrafi MM, Fernandez ML. Bioactive Components in *Moringa Oleifera* Leaves Protect against Chronic Disease. *Antioxidants (Basel)*. 2017; 6(4): 91. DOI: 10.3390/antiox6040091.
14. Ansori ANM, Susilo RJK, Fadholly A, Hayaza S, Nugraha AP, Husen SA. Antidiabetes type 2 phytomedicine: Mangosteen (*Garcinia Mangostana* L.)-A review. *Biochem Cell Arch*. 2020; 20: 3173-3177. DOI: 10.35124/bca.2020.20.S1.3173
15. Khairullah AR, Solikhah TI, Ansori ANM, Fadholly A, Ramandinianto SC, Ansharieta R, Widodo A, Riwu KHP, Putri N, Proboningrat A, Kusala MKJ, Rendragraha BW, Putra ARS, Anshori A. A Review of an Important Medicinal Plant: *Alpinia galanga* (L.) Willd. *Sys Rev Pharm*. 2020; 11(10): 387-395. DOI: 10.31838/srp.2020.10.62
16. Kharisma VD, Widyananda MH, Ansori ANM, Nege AS, Naw SW, Nugraha AP. Tea catechin as antiviral agent via apoptosis agonist and triple inhibitor mechanism against HIV-1 infection: A bioinformatics approach. *J Pharm Pharmacogn Res*. 9(4): 435-445.
17. Kharisma VD, Ansori ANM, Widyananda MH, Utami SL, Nugraha AP. Molecular simulation: The potency of conserved region on E6 HPV-16 as a binding target of black tea compounds against cervical cancer. *Biochem Cell Arch*. 2020; 20: 2795-2802. DOI: 10.35124/bca.2020.20.S1.2795
18. Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori ANM, Antonius Y (2021) Molecular docking study of sea urchin (*Arbacia lixula*) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. *J Pharm Pharmacogn Res* 9(4): 484–496.
19. Tacharina MR, Ansori ANM, Plumeriastuti H, Kusnoto, Kurnijasanti R, Hestianah EP. Beneficial effect of grinting grass (*Cynodon dactylon*) on the streptozotocin induced diabetes mellitus in the mice. *Indian Vet J*. 2020; 97(4): 35-38.
20. Wahyuni DK, Ansori ANM, Vidiyanti F. GC-MS analysis of phytocomponents in methanolic extracts of leaf-derived callus of *Justicia gendarussa* Burm.f. *Biosci Res*. 2017;14(3):668-677.
21. Husen SA, Winarni D, Salamun, Ansori ANM, Susilo RJK, Hayaza S. Hepatoprotective Effect of Gamma-mangostin for Amelioration of Impaired Liver Structure and Function in Streptozotocin-induced Diabetic Mice. *IOP Conf Ser: Earth Env Sci*. 2019; 217(1): 012031. DOI: 10.1088/1755-1315/217/1/012031
22. Ansori ANM, Kusala MKJ, Irawan H, Putri N, Fadholly A, Proboningrat A, Rukmana Siti, Karni I, Anisa AK, Adrianto H. Citrus *reticulata* extract as biocides to control *Aedes aegypti*, the vector of dengue. *Biosci Res*. 2018; 15(3): 1661-1665.
23. Ansori ANM, Sucipto TH, Chylichcova S, Padmi H, Kharisma VD, Widyananda MH, Ullah E, Gumenyuk O, Prasedya ES, Sibero MT, Bratishko N, Zainul R. Macroalgae Bioactive Compounds for the Potential Antiviral of SARS-CoV-2: An In Silico Study. *Journal*

- of Pure and Applied Microbiology. 2022; 16(2): 1018-1027. DOI: 10.22207/JPAM.16.2.26
24. Fadholly A, Ansori ANM, Utomo B. Anticancer Effect of Naringin on Human Colon Cancer (WiDr Cells): In Vitro Study. *Research Journal of Pharmacy and Technology*. 2022; 15(2): 885-888. DOI: 10.52711/0974-360X.2022.00148
 25. Dibha AF, Wahyuningsih S, Ansori ANM, Kharisma VD, Widyananda MH, Parikesit AA, Sibero MT, Probojati RT, Murtadlo AAA, Trinugroho JP, Sucipto TH, Turista DDR, Rosadi I, Ullah ME, Jakhmola V, Zainul R. Utilization of Secondary Metabolites in Algae *Kappaphycus alvarezii* as a Breast Cancer Drug with a Computational Method. *Pharmacognosy Journal*. 2022; 14(3): 536-543. DOI: 10.5530/pj.2022.14.68
 26. Aini NS, Ansori ANM, Kharisma VD, Syadzha MF, Widyananda MH, Murtadlo AA, et al. Potential Roles of Purslane (*Portulaca oleracea* L.) as Antimetabolic Syndrome: A Review. *Pharmacognosy Journal*. 2022; 14(3): 710-714. DOI: 10.5530/pj.2022.14.90
 27. Listiyani P, Kharisma VD, Ansori AN, Widyananda MH, Probojati RT, Murtadlo AA, et al. In Silico Phytochemical Compounds Screening of *Allium sativum* Targeting the Mpro of SARS-CoV-2. *Pharmacognosy Journal*. 2022; 14(3): 604-609. DOI: 10.5530/pj.2022.14.78
 28. Naw SW, Probojati RT, Murtadlo, AAA, Ullah, ME. (2022). Computational Drug Design Study of *Curcuma longa* L. Compound as HPV-16 Antiviral Candidate Against Cervical Cancer. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics*, 1(01), 1–6.
 29. Ullah ME, Probojati RT, Murtadlo AAA, Tamam MB, Naw WR. Revealing of Antiinflammatory Agent from *Zingiber officinale* var. *Roscoe* via IKK-B Inhibitor Mechanism through In Silico Simulation. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics*. 2022; 1(01): 14–19.
 30. Ullah ME, Naw WR, Murtadlo AAA, Tamam MB, Probojati RT. Molecular Mechanism of Black Tea (*Camellia sinensis*) as SARS-CoV-2 Spike Glycoprotein Inhibitor through Computational Approach. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics*. 2022; 1(01): 20–25.
 31. Probojati RT, Murtadlo AAA, Ullah ME, Naw WR, Turista DDR. Molecular Docking Study of HIV-1 Antiretroviral Candidate via Reverse Transcriptase Inhibitor from *Zingiber officinale* var. *Roscoe*. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics*. 2022; 1(01): 26–31.
 32. Tamam MB, Naw WR, Ullah ME, Probojati RT, Murtadlo AAA, Turista DDR. Virtual Screening of *Kaempferia galanga* L. Bioactive Compounds as HPV-16 Antiviral Mechanism Through E6 Inhibitor Activity. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics*. 2022; 1(01): 7–13.
 33. Ansori ANM, Fadholly A, Hayaza S, Susilo RJK, Inayatillah B, Winarni D, Husen SA. A Review on Medicinal Properties of Mangosteen (*Garcinia mangostana* L.). *Res J Pharm Technol*. 2020; 13(2):974-982. doi: 10.5958/0974-360X.2020.00182.1
 34. Husen SA, Wahyuningsih SPA, Ansori ANM, Hayaza S, Susilo RJK, Winarni D, Punnapayak H, Darmanto W. Antioxidant Potency of Okra (*Abelmoschus esculentus* Moench) Pods Extract on SOD Level and Tissue Glucose Tolerance in Diabetic Mice. *Res J Pharm Technol*. 12(12): 5683. doi: 10.5958/0974-360X.2019.00983.1
 35. Husen SA, Setyawan MF, Syadzha MF, Susilo RJK, Hayaza S, Ansori ANM, Alamsjah MA, Ilmi ZN, Wulandari PAC, Pudjiastuti P, Awang P, Winarni D. A Novel Therapeutic effects of *Sargassum ilicifolium* Alginate and Okra (*Abelmoschus esculentus*) Pods extracts on Open wound healing process in Diabetic Mice. *Research J. Pharm. and Tech* 2020; 13(6): 2764-2770. doi: 10.5958/0974-360X.2020.00491.6
 36. Kharisma VD, Kharisma SD, Ansori ANM, Kurniawan HP, Witaningrum AM, Fadholly A, Tacharina MR. Antiretroviral Effect Simulation from Black Tea (*Camellia sinensis*) via Dual Inhibitors Mechanism in HIV-1 and its Social Perspective in Indonesia. *Res J Pharm Technol*. 2021; 14(1): 455-460. doi: 10.5958/0974-360X.2021.00083.4
 37. Fadholly A, Ansori ANM, Kharisma VD, Rahmahani J, Tacharina MR. Immunobioinformatics of Rabies Virus in Various Countries of Asia: Glycoprotein Gene. *Res J Pharm Technol*. 2021; 14(2): 883-886. doi: 10.5958/0974-360X.2021.00157.8
 38. Ansori ANM, Fadholly A, Proboningrat A, Hayaza S, Susilo RJK, Naw SW, Posa GAV, Yusrizal YF, Sibero MT, Sucipto TH, Soegijanto S. In vitro antiviral activity of *Pinus merkusii* (Pinaceae) stem bark and cone against dengue virus type-2 (DENV-2). *Res J Pharm Technol*. 2021; 14(7):3705-8. doi: 10.52711/0974-360X.2021.00641

39. Ansori ANM, Kharisma VD, Fadholly A, Tacharina MR, Antonius Y, Parikesit AA. Severe Acute Respiratory Syndrome Coronavirus-2 Emergence and Its Treatment with Alternative Medicines: A Review. *Research Journal of Pharmacy and Technology* 2021; 14(10):5551-7. doi: 10.52711/0974-360X.2021.00967
40. Husen SA, Ansori ANM, Hayaza S, Susilo RJK, Zuraidah AA, Winarni D, Punnapayak H, Darmanto W. Therapeutic Effect of Okra (*Abelmoschus esculentus* Moench) Pods Extract on Streptozotocin-Induced Type-2 Diabetic Mice. *Res J Pharm Technol.* 2019; 12(8):3703-3708. doi: 10.5958/0974-360X.2019.00633.4
41. Ansori ANM, Kharisma VD, Solikhah TI. Medicinal properties of *Muntingia calabura* L.: A Review. *Res J Pharm Technol.* 2021; 14(8):4509-2. doi: 10.52711/0974-360X.2021.00784
42. Proboningrat A, Kharisma VD, Ansori ANM, Rahmawati R, Fadholly A, Posa GAV, Sudjarwo SA, Rantam FA, Achmad AB. In silico Study of Natural inhibitors for Human papillomavirus-18 E6 protein. *Res J Pharm Technol.* 2022; 15(3):1251-6. doi: 10.52711/0974-360X.2022.00209
43. Kharisma VD, Ansori ANM, Jakhmola V, Rizky WC, Widyananda MH, Probojati RT, Murtadlo AAA, Rebezov M, Scherbakov P, Burkov P, Matrosova Y, Romanov A, Sihombing MAEM, Antonius Y, Zainul R. Multi-strain human papillomavirus (HPV) vaccine innovation via computational study: A mini review. *Res J Pharm Technol.* 2022; 15(8).